Aethlon Medical Faces Delisting Concerns

TL;DR

AETH stock might be delisted - check exchange rules!

AI Summary

Aethlon Medical, Inc. filed an 8-K on October 22, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is incorporated in Nevada and its principal executive offices are located in San Diego, California.

Why It Matters

This filing indicates potential issues with Aethlon Medical's compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.

Key Players & Entities

• Aethlon Medical, Inc. (company) — Registrant
• October 22, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• San Diego, California (location) — Address of principal executive offices
• 001-37487 (identifier) — Commission File Number
• 13-3632859 (identifier) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq
• $1.00 — or the Company's common stock was below $1.00 per share for 30 consecutive business d

Filing Documents

• aethlon_8k.htm (8-K) — 28KB
• 0001683168-25-007719.txt ( ) — 191KB
• aemd-20251022.xsd (EX-101.SCH) — 3KB
• aemd-20251022_lab.xml (EX-101.LAB) — 33KB
• aemd-20251022_pre.xml (EX-101.PRE) — 22KB
• aethlon_8k_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 16, 2025, Aethlon Medical, Inc. (the "Company") received a notification letter (the "Notice") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, because the closing bid price for the Company's common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Requirement") and subject to the compliance and delisting provisions of Rule 5810(c)(3)(A) and (iv) thereunder. The Company has filed a request for a hearing before the Nasdaq Hearings Panel (the "Panel"). The hearing request will automatically stay any suspension or delisting action by Nasdaq pending the panel's decision, and the Company's common stock will continue to trade on Nasdaq Capital Market under the symbol "AEMD". As part of its plan to regain compliance with Nasdaq listing requirements, the Company has already implemented a 1-for-10 reverse stock split of its common stock, which became effective on October 16 and began trading on October 20, 2025. The Company is monitoring the closing bid price of its common stock and will evaluate additional actions as appropriate to maintain its listing on the Nasdaq Capital Market.

Forward-Looking Statements

Forward-Looking Statements Certain information contained in this Current Report on Form 8-K includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "intends," "believes," "potential," "anticipates," "estimates," "expects," "plans," "may," "could," "might," "likely," "will," "should" or other words that convey the uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking assumptions, and uncertainties, including statements regarding our plans to appeal the delisting determination, our ability to regain compliance with Nasdaq's continued listing requirements and the outcome of any hearing we might request. Any or all of the forward-looking and uncertainties. These forward-looking statements are subject to risks and uncertainties, including risks related to our ability to regain compliance with Nasdaq's continued listing requirements or otherwise maintain compliance with any other listing requirement of the Nasdaq Capital Market, the potential delisting of our shares from the Nasdaq Capital Market due to our failure to comply with the applicable rules, and the other risks set forth in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking

forward-looking statements to reflect subsequent events or circumstances unless required by law

forward-looking statements to reflect subsequent events or circumstances unless required by law. 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2025 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Chief Executive Officer and Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR